Trial · NCT02217501
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
NCT02217501, Phase 3, Completed, University of Texas Southwestern Medical Center; results first posted 2021-02-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities. Trials, record NCT02217501. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02217501
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
- NCT number
- NCT02217501
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 159 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Peripheral Arterial Disease
- Interventions
- Clopidogrel, Acetylsalicylic acid (ASA)
- First posted
- 2014-08-15
- Last updated
- 2021-02-21
- Results first posted
- 2021-02-21
- Limitations and caveats
- Study was not able to reach the target number of participants needed to achieve target power and statistically reliable results.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death | 12 months from index procedure or end of study treatment, whichever is longer, assessed up to 2 years | Occlusion of the target vessel documented by any imaging procedure (eg, Duplex ultrasonography scan including B mode imaging and Doppler ultrasound scan) at any follow-up visit within 12 months or end of study treatment period, whichever is longer. |
| Secondary | Number of Participants With First Occurrence of Bleeding | 12 months from index procedure or end of study treatment, whichever is longer, assessed up to 2 years | Any mild, moderate, severe, or life-threatening bleeding. Severe or Life-threatening: Intracerebral hemorrhage Resulting in substantial hemodynamic compromise requiring treatment Moderate: Requiring blood transfusion but not resulting in hemodynamic compromise Mild: Bleeding that does not meet above criteria Severe bleeding defined according to the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) classification. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death | 12 months from index procedure or end of study treatment, whichever is longer, assessed up to 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With First Occurrence of Bleeding | 12 months from index procedure or end of study treatment, whichever is longer, assessed up to 2 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death | DAPT - Clinically Indicated Duration+12m | 13 | Participants | ||
| Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death | DAPT - Clinically Indicated Duration | 16 | Participants | ||
| Number of Participants With First Occurrence of Bleeding | DAPT - Clinically Indicated Duration+12m | 5 | Participants | ||
| Number of Participants With First Occurrence of Bleeding | DAPT - Clinically Indicated Duration | 4 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | DAPT - Clinically Indicated Duration+12m | 77 | |
| Overall Study | STARTED | DAPT - Clinically Indicated Duration | 82 | |
| Overall Study | COMPLETED | DAPT - Clinically Indicated Duration+12m | 74 | |
| Overall Study | COMPLETED | DAPT - Clinically Indicated Duration | 78 | |
| Overall Study | NOT COMPLETED | DAPT - Clinically Indicated Duration+12m | 3 | |
| Overall Study | NOT COMPLETED | DAPT - Clinically Indicated Duration | 4 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | CT/MR Angiography | Surgical and medical procedures | DAPT - Clinically Indicated Duration+12m | 1 | 77 | 1 |
| other | CT/MR Angiography | Surgical and medical procedures | DAPT - Clinically Indicated Duration | 1 | 82 | 1 |
| serious | Myocardial Infarction | Cardiac disorders | DAPT - Clinically Indicated Duration+12m | 1 | 77 | 1 |
| serious | Myocardial Infarction | Cardiac disorders | DAPT - Clinically Indicated Duration | 3 | 82 | 3 |
| serious | Stroke | Blood and lymphatic system disorders | DAPT - Clinically Indicated Duration+12m | 1 | 77 | 1 |
| serious | Stroke | Blood and lymphatic system disorders | DAPT - Clinically Indicated Duration | 2 | 82 | 2 |
| serious | Repeat Endovascular Revascularization | Vascular disorders | DAPT - Clinically Indicated Duration+12m | 13 | 77 | 13 |
| serious | Repeat Endovascular Revascularization | Vascular disorders | DAPT - Clinically Indicated Duration | 16 | 82 | 16 |
| serious | Amputation | Surgical and medical procedures | DAPT - Clinically Indicated Duration+12m | 7 | 77 | 7 |
| serious | Amputation | Surgical and medical procedures | DAPT - Clinically Indicated Duration | 12 | 82 | 12 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DAPT - Clinically Indicated Duration+12m | 3 | 77 |
| Total, all-cause mortality | DAPT - Clinically Indicated Duration | 4 | 82 |
| Total, other adverse events | DAPT - Clinically Indicated Duration+12m | 1 | 77 |
| Total, other adverse events | DAPT - Clinically Indicated Duration | 1 | 82 |
| Total, serious adverse events | DAPT - Clinically Indicated Duration+12m | 27 | 77 |
| Total, serious adverse events | DAPT - Clinically Indicated Duration | 37 | 82 |
Source ClinicalTrials.gov
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: Number of Participants With First Occurrence of Bleeding | Trial comparisons |
| DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: deaths from any cause | Trial comparisons |
DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death | Trial comparisons |
| DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02217501
GET https://conductscience.org/api/trials/v1/NCT02217501/registered